Literature DB >> 21151154

Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

Roberta Mazzucchelli1, Doriana Morichetti, Marina Scarpelli, Aldo V Bono, Antonio Lopez-Beltran, Liang Cheng, Ziya Kirkali, Rodolfo Montironi.   

Abstract

The aim of this study was to examine the tissue expression and localisation of the somatostatin receptors (SSTRs) in hormone-refractory (HR) prostate cancer (PCa). Five SSTRs were evaluated immunohistochemically in 20 radical prostatectomies (RPs) with Gleason score (GS) 3+3=6 PCa, in 20 RPs with GS 4+4=8 and 4+5=9 PCa, and 20 transurethral resection of the prostate specimens with HR PCa. The mean values in the cytoplasm (all five SSTRs were expressed), membrane (only SSTR3 and SSTR4 were expressed) and nuclei (only SSTR4 and SSTR5 were expressed) of the glands in HR PCa were 20-70% lower than in the other two groups, the differences being statistically significant. All five SSTRs were expressed in the smooth muscle and endothelial cells of HR PCa, the mean values being lower than in the other two groups. In conclusion, this study expands our knowledge on the expression and localisation of five SSTRs in the various tissue components in the HR PCa compared with hormone-sensitive PCa.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21151154      PMCID: PMC3739180          DOI: 10.1038/aja.2010.100

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  30 in total

1.  Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.

Authors:  D Morichetti; R Mazzucchelli; A Santinelli; D Stramazzotti; A Lopez-Beltran; M Scarpelli; A V Bono; L Cheng; R Montironi
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Apr-Jun       Impact factor: 3.219

Review 2.  Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Authors:  Michael Koutsilieris; John Bogdanos; Constantine Milathianakis; Peter Dimopoulos; Theodoros Dimopoulos; Dimitrios Karamanolakis; Antonis Halapas; Roxane Tenta; Haralampos Katopodis; Effie Papageorgiou; Nea Pitulis; Nikos Pissimissis; Peter Lembessis; Antigone Sourla
Journal:  Expert Opin Investig Drugs       Date:  2006-07       Impact factor: 6.206

3.  Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.

Authors:  Marco Volante; Maria Pia Brizzi; Antongiulio Faggiano; Stefano La Rosa; Ida Rapa; Anna Ferrero; Gelsomina Mansueto; Luisella Righi; Silvana Garancini; Carlo Capella; Gaetano De Rosa; Luigi Dogliotti; Annamaria Colao; Mauro Papotti
Journal:  Mod Pathol       Date:  2007-09-14       Impact factor: 7.842

Review 4.  Somatostatin receptors: from basic science to clinical approach--thyroid.

Authors:  M C Zatelli; E C degli Uberti
Journal:  Dig Liver Dis       Date:  2004-02       Impact factor: 4.088

5.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 6.  Chemotherapy targeted to cancers through tumoral hormone receptors.

Authors:  Andrew V Schally; Attila Nagy
Journal:  Trends Endocrinol Metab       Date:  2004-09       Impact factor: 12.015

7.  Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction.

Authors:  Rodolfo Montironi; Liang Cheng; Roberta Mazzucchelli; Doriana Morichetti; Daniela Stramazzotti; Alfredo Santinelli; Gianluca Moroncini; Andrea B Galosi; Giovanni Muzzonigro; Giancarlo Comeri; Jon Lovisolo; Sergio Cosciani-Cunico; Aldo V Bono
Journal:  Cell Oncol       Date:  2008       Impact factor: 6.730

8.  Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

Authors:  Markus Letsch; Andrew V Schally; Karoly Szepeshazi; Gabor Halmos; Attilla Nagy
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.

Authors:  Jens Hansson; Anders Bjartell; Virgil Gadaleanu; Nishtman Dizeyi; Per-Anders Abrahamsson
Journal:  Prostate       Date:  2002-09-15       Impact factor: 4.104

10.  Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.

Authors:  G Verset; C Verslype; H Reynaert; I Borbath; P Langlet; A Vandebroek; M Peeters; G Houbiers; S Francque; M Arvanitakis; J-L Van Laethem
Journal:  Br J Cancer       Date:  2007-08-07       Impact factor: 7.640

View more
  1 in total

1.  Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis.

Authors:  Yo-Liang Lai; Chia-Hsin Liu; Shu-Chi Wang; Shu-Pin Huang; Yi-Chun Cho; Bo-Ying Bao; Chia-Cheng Su; Hsin-Chih Yeh; Cheng-Hsueh Lee; Pai-Chi Teng; Chih-Pin Chuu; Deng-Neng Chen; Chia-Yang Li; Wei-Chung Cheng
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.